AbbVie Asks Fed. Circ. To Revive Antibody Patent Suit
AbbVie Deutschland GmbH & Co. on Monday asked the Federal Circuit to reverse a jury's decision invalidating as obvious a pair of patents covering genetically engineered human antibodies to interleukin 12,...To view the full article, register now.
Already a subscriber? Click here to view full article